Agile Therapeutics Inc. (NASDAQ:AGRX) trading with a subtraction of -$0.27 to $0.67 on Friday, a downside of -29.00 percent. An average of 1,870,243 shares of common stock have been traded in the last five days. There was a fall of -$0.3255 in the past week. The last 20 days have seen an average of 872,631 shares traded, while the 50-day average volume stands at 731,272.
AGRX stock has decreased by -20.82% in the last month. The company shares reached their 1-month lowest point of $0.6560 on 10/08/21. With the stock rallying to its 52-week high on 02/16/21, shares of the company touched a low of $0.91 and a high of $3.77 in 52 weeks. In spite of this, the price is down -82.25% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Agile Therapeutics Inc. (AGRX) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 31.96 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 1.02. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 40.52, the price-to-book (PB) ratio at 3.37.
The quick ratio of Agile Therapeutics Inc. for the three months ended June 29 was 2.90, and the current ratio was 3.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.65 and a total debt to equity ratio of 0.65 for the quarter ending June 29. Agile Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -6512.28%. Its gross profit as reported stood at $0.47 million compared to revenue of $0.75 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Agile Therapeutics Inc.’s return on assets was -99.10%, compared to -58.1% over the last five years. In the past year, the return on investment has been -74.70%, and the 5-year average is -61.8%. Meanwhile, the return on equity (ROE) for the past 12 months has been -155.10% and the 5-year average holds at -77.5%. For the broader industry, ROE averaged -15.50 over the past year.
For the three-month period that ended June 29, Agile Therapeutics Inc. had $5.0 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.19 million in the quarter, while revenues of $0.12 million were grew 100.0%. The analyst consensus anticipated Agile Therapeutics Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.2, a 9.10% surprise. For the quarter, EBITDA amounted to -$16.1 million. Shareholders own equity worth $93.0 million.
From a technical analysis perspective, let’s take a brief look at Agile Therapeutics Inc. (AGRX) price momentum. RSI 9-day as of the close on 07 October was 12.27%, suggesting the stock is oversold, with historical volatility in this time frame at 168.35%.
As of today, AGRX’s price is $0.9035 -32.88% or -$0.3255 from its 5-day moving average. AGRX is currently trading -43.21% lower than its 20-day SMA and -58.21% lower than its 100-day SMA. However, the stock’s current price level is -45.08% below the SMA50 and -77.63% below the SMA200.
The stochastic %K and %D were 14.15% and 25.53%, respectively, and the average true range (ATR) was 0.0754. With the 14-day stochastic at 2.10% and the average true range at 0.0675, the RSI (14) stands at 19.73%. The stock has reached -0.0844 on the 9-day MACD Oscillator while the 14-day reading was at -0.1180.
The consensus rating for Agile Therapeutics Inc. (AGRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AGRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is AGRX’s price target for the next 12 months?
Analysts predict a range of price targets between $3.50 and $5.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for Agile Therapeutics Inc. (AGRX) stock is $4.13.